Sonam Puri
( out of 162 reviews )

Sonam Puri, MD

Languages spoken: English, Panjabi, Hindi

  • Dr Sonam Puri MD. is an Assistant Professor in the Division of Oncology, Department of Medicine at the University of Utah. She is a specialist in medical oncology with a focus on the treatment of thoracic malignancies. She is originally from New Delhi, India and earned her medical degree from Pandit B.D Sharma PGIMS Rohtak, Haryana. She then completed her Internal Medicine Residency at the University of Connecticut Health Center in Farmington, Connecticut and fellowship in Hematology and Oncology at H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida in Tampa, Florida.

    Dr Puri’s research interests include clinical research in thoracic malignancies, with emphasis on immunotherapy, targeted therapy and other novel treatment strategies for non-small and small cell lung cancer. She is an active member of the Lung Cancer Disease Center of Excellence at the Huntsman cancer institute. She is also a member of several national and international professional organizations like American Society of Medical Oncology, Southwest Oncology Group, Society of Immunotherapy of Cancer and International association of study of lung cancer where she serves as a member of the membership committee.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Patient Rating

    4.8 /5
    ( out of 162 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 25, 2023

    She is very efficient and caring and makes sure you understand your care.

    August 06, 2023

    Informative

    July 23, 2023

    Very caring and intelligent

    See More Patient Comments

  • Dr Sonam Puri MD. is an Assistant Professor in the Division of Oncology, Department of Medicine at the University of Utah. She is a specialist in medical oncology with a focus on the treatment of thoracic malignancies. She is originally from New Delhi, India and earned her medical degree from Pandit B.D Sharma PGIMS Rohtak, Haryana. She then completed her Internal Medicine Residency at the University of Connecticut Health Center in Farmington, Connecticut and fellowship in Hematology and Oncology at H. Lee Moffitt Cancer Center and Research Institute/ University of South Florida in Tampa, Florida.

    Dr Puri’s research interests include clinical research in thoracic malignancies, with emphasis on immunotherapy, targeted therapy and other novel treatment strategies for non-small and small cell lung cancer. She is an active member of the Lung Cancer Disease Center of Excellence at the Huntsman cancer institute. She is also a member of several national and international professional organizations like American Society of Medical Oncology, Southwest Oncology Group, Society of Immunotherapy of Cancer and International association of study of lung cancer where she serves as a member of the membership committee.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    Educational Commission for Foreign Medical Graduates

    Education history

    Fellowship Hematology and Oncology - University of South Florida, H. Lee Moffitt Cancer Center & Research Institute Fellow
    Internal Medicine, Clinical Educator Track - University of Connecticut School of Medicine Intern/Resident
    Undergraduate Medicine; Surgery - Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences M.D.

    Selected Publications

    Journal Article

    1. Cannon-Albright LA, Teerlink CC, Stevens J, Facelli JC, Carr SR, Allen-Brady K, Puri S, Bailey-Wilson JE, Musolf AM, Genetic Epidemiology of Lung Cancer Consortium, Akerley W (2023). A rare FGF5 candidate variant (rs112475347) for predisposition to nonsquamous, nonsmall-cell lung cancer. Int J Cancer.
    2. Sama S, Kerrigan K, Sinnott JA, Puri S, Akerley W, Haaland B, Patel S (2023). Real-world comparison of survival outcomes with cisplatin versus carboplatin in patients with limited-stage small-cell lung cancer. Cancer Treat Res Commun, 35, 100686.
    3. Wang X, Kerrigan K, Puri S, Shen J, Akerley W, Haaland B (2022). Dynamic Prediction of Near-Term Overall Survival in Patients with Advanced NSCLC Based on Real-World Data. Cancers (Basel), 14(3).
    4. Whisenant JG, Baena J, Cortellini A, Huang LC, Lo Russo G, Porcu L, Wong SK, Bestvina CM, Hellmann MD, Roca E, Rizvi H, Monnet I, Boudjemaa A, Rogado J, Pasello G, Leighl NB, Arrieta O, Aujayeb A, Batra U, Azzam AY, Unk M, Azab MA, Zhumagaliyeva AN, Gomez-Martin C, Blaquier JB, Geraedts E, Mountzios G, Serrano-Montero G, Reinmuth N, Coate L, Marmarelis M, Presley CJ, Hirsch FR, Garrido P, Khan H, Baggi A, Mascaux C, Halmos B, Ceresoli GL, Fidler MJ, Scotti V, Mtivier AC, Falchero L, Felip E, Genova C, Mazieres J, Tapan U, Brahmer J, Bria E, Puri S, Popat S, Reckamp KL, Morgillo F, Nadal E, Mazzoni F, Agustoni F, Bar J, Grosso F, Avrillon V, Patel JD, Gomes F, Ibrahim E, Trama A, Bettini AC, Barlesi F, Dingemans AM, Wakelee H, Peters S, Horn L, Garassino MC, Torri V, TERAVOLT study group (2022). A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol, 17, 661-674.
    5. Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (2022). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. JTO Clin Res Rep, 3(3), 100280.
    6. Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, Khan H, Mamdani H, Nagasaka M, Puri S, Liu SV, Korn WM, Nieva JJ (2021). Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget, 12(25), 2449-2458.
    7. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, DAmico TA, DAvella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M (2021). Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 19(12), 1441-1464.
    8. Nagasaka M, Asad MFB, Al Hallak MN, Uddin MH, Sukari A, Baca Y, Xiu J, Magee D, Mamdani H, Uprety D, Kim C, Xia B, Liu SV, Nieva JJ, Lopes G, Bepler G, Borghaei H, Demeure MJ, Raez LE, Ma PC, Puri S, Korn WM, Azmi AS (2021). Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 160, 92-98.
    9. Kerrigan K, Wang X, Haaland B, Adamson B, Patel S, Puri S, Akerley W (2021). Real World Characterization of Advanced Non-Small Cell Lung Cancer in Never Smokers by Actionable Mutation Status. Clin Lung Cancer, 22(4), 260-267.e2.
    10. Kulkarni AA, Naqash AR, Puri S, Dienstmann R (2021). Is It Time to Implement Adjuvant Targeted Therapy in EGFR-Mutant Non-Small-Cell Lung Cancer? JCO Precis Oncol, 5.
    11. Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsk S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, Oliver TG (2020). MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. Cancer Cell, 38(1), 60-78.e12.
    12. Puri S, Saltos A, Perez B, Le X, Gray JE (2020). Locally Advanced, Unresectable Non-Small Cell Lung Cancer. Curr Oncol Rep, 22(4), 31.
    13. Sandoval-Sus JD, Faramand R, Chavez J, Puri S, Parra P, Sokol L, Kharfan-Dabaja MA, Shah B, Ayala E (2018). Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study. Leuk Lymphoma, 60(2), 309-316.
    14. Puri S, Markowitz J (2017). The use of baseline biomarkers to predict outcome in melanoma patients treated with pembrolizumab. Ann Res Hosp, 1.
    15. Gupta T, Parikh K, Puri S, Agrawal S, Agrawal N, Sharma D, DeLorenzo L (2014). The forgotten disease: Bilateral lemierre's disease with mycotic aneurysm of the vertebral artery. Am J Case Rep, 15, 230-4.

    Review

    1. Higgins KA, Puri S, Gray JE (2022). Systemic and Radiation Therapy Approaches for Locally Advanced Non-Small-Cell Lung Cancer. [Review]. J Clin Oncol, 40(6), 576-585.
    2. Kerrigan K, Puri S (2022). Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. [Review]. Curr Oncol Rep, 24(1), 113-123.
    3. Naqash AR, Kihn-Alarcn AJ, Stavraka C, Kerrigan K, Maleki Vareki S, Pinato DJ, Puri S (2020). The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. [Review]. Ann Transl Med, 9(12), 1034.
    4. Florou V, Puri S, Garrido-Laguna I, Wilky BA (2020). Considerations for immunotherapy in patients with cancer and comorbid immune dysfunction. [Review]. Ann Transl Med, 9(12), 1035.
    5. Bindal P, Gray JE, Boyle TA, Florou V, Puri S (2020). Biomarkers of therapeutic response with immune checkpoint inhibitors. [Review]. Ann Transl Med, 9(12), 1040.
    6. Puri S, Shafique M (2020). Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies. [Review]. Drugs Context, 9.
    7. Puri S, Shafique M, Gray JE (2018). Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. [Review]. Curr Treat Options Oncol, 19(8), 39.

    Editorial

    1. Puri S, Lok BH, Leighl N, Gray JE (2020). Editorial: Update on the Biology, Management, and Treatment of Small Cell Lung Cancer. Front Oncol, 10, 1783.

    Letter

    1. Smith JT, Puri S, Akerley W (2023). Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib. [Letter to the editor]. Clin Lung Cancer.